WCLC 2025 - Posters & ePosters-P3.18.42 Camrelizumab Combined With Chemotherapy and Local Consolidative Therapy for Untreated Oligometastatic NSCLC With PD-L1 Expression <50%

P3.18.42 Camrelizumab Combined With Chemotherapy and Local Consolidative Therapy for Untreated Oligometastatic NSCLC With PD-L1 Expression <50%

Asset Subtitle

Li Ping Lin

Meta Tag

Speaker Li Ping Lin

Topic Clinical Trials in Progress